Pulmonary Nocardiosis in a Multiple Myeloma Patient Treated with Proteasome Inhibitors

被引:5
|
作者
Mendonca, Nikolai P. [1 ]
Kadayakkara, Deepak K. [1 ]
Forde, Inga C. [1 ]
Rudkovaskaia, Anastasiia [1 ]
Saul, Zane K. [1 ]
Lobo, David J. [1 ]
机构
[1] Bridgeport Hosp, Yale New Haven Hlth, Dept Internal Med, Bridgeport, CT USA
来源
关键词
Lymphopenia; Multiple Myeloma; Nocardia; Proteasome Inhibitors;
D O I
10.12659/AJCR.896280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Rare co-existance of disease or pathology Background: The use of proteasome inhibitors like Bortezomib to treat multiple myeloma has been associated with increased rates of opportunistic infections, including Nocardia, especially when lymphopenia is present. The prevalence or association of such infections with newer agents like Carfilzomib is not known. Case Report: A 71-year-old man with multiple myeloma presented with a 6-week history of respiratory symptoms and cyclic fevers. He was undergoing chemotherapy with Carfilzomib. Work-up revealed severe lymphopenia and a CT chest showed multiple lung nodules and a mass-like consolidation. He underwent a bronchoscopy, and respiratory cultures grew Nocardia species. He responded well to intravenous antibiotics with resolution of symptoms and CT findings. Conclusions: With the introduction of newer agents like Carfilzomib for the treatment of multiple myeloma, clinicians must maintain a high degree of suspicion for opportunistic infections to achieve early diagnosis and treatment.
引用
收藏
页码:76 / 78
页数:3
相关论文
共 50 条
  • [1] The proteasome and proteasome inhibitors in multiple myeloma
    Sara Gandolfi
    Jacob P. Laubach
    Teru Hideshima
    Dharminder Chauhan
    Kenneth C. Anderson
    Paul G. Richardson
    Cancer and Metastasis Reviews, 2017, 36 : 561 - 584
  • [2] The proteasome and proteasome inhibitors in multiple myeloma
    Gandolfi, Sara
    Laubach, Jacob P.
    Hideshima, Teru
    Chauhan, Dharminder
    Anderson, Kenneth C.
    Richardson, Paul G.
    CANCER AND METASTASIS REVIEWS, 2017, 36 (04) : 561 - 584
  • [3] Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany
    Steinmetz, H. Tilman
    Singh, Moushmi
    Lebioda, Andrea
    Gonzalez-McQuire, Sebastian
    Rieth, Achim
    Schoehl, Martina
    Poenisch, Wolfram
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (09) : 449 - 459
  • [4] Proteasome inhibitors for multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (09) : 785 - 792
  • [5] Proteasome Inhibitors in Multiple Myeloma
    Anderson, Kenneth C.
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : S20 - S26
  • [6] Novel proteasome inhibitors in multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (05): : 370 - 372
  • [7] Proteasome inhibitors in the treatment of multiple myeloma
    J J Shah
    R Z Orlowski
    Leukemia, 2009, 23 : 1964 - 1979
  • [8] Proteasome inhibitors in the treatment of multiple myeloma
    McBride, Ali
    Ryan, Patricia Y.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (03) : 339 - 358
  • [9] Proteasome Inhibitors for the Treatment of Multiple Myeloma
    Ito, Shigeki
    CANCERS, 2020, 12 (02)
  • [10] Proteasome inhibitors for the treatment of multiple myeloma
    Scalzulli, Emilia
    Grammatico, Sara
    Vozella, Federico
    Petrucci, Maria Teresa
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 375 - 386